Immix Biopharma (IMMX) Stock Price, News & Analysis

Company Overview

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment. IMX-110 is currently being evaluated in early-phase clinical trials, with initial data assessing safety, tolerability and preliminary signs of clinical benefit. In addition to its flagship program, Immix Biopharma is advancing a pipeline of next-generation myeloid modulators in preclinical development, seeking to expand application across multiple tumor types.

Headquartered in the United States, Immix Biopharma operates research and development facilities dedicated to advancing its immuno-oncology platform through early clinical stages. The management team brings together seasoned professionals in oncology drug development and translational research, supported by collaborations with leading academic and clinical institutions. With a commitment to addressing unmet needs in cancer care, Immix Biopharma is positioned to translate innovative science into potential new therapies for patients worldwide.

Key Stats

• Today's Range: $2.18 to $2.33
• 50-Day Range: $1.96 to $2.99
• 52-Week Range: $1.26 to $3.20
• Volume: 63,565 shs
• Average Volume: 167,238 shs
• Market Capitalization: $63.14 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.00
• Consensus Rating: Moderate Buy

Immix Biopharma Stock Analysis - MarketRank™

Immix Biopharma scored higher than 66% of companies evaluated by MarketBeat, and ranked 331st out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Immix Biopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Upside Potential

Immix Biopharma has a consensus price target of $7.00, representing about 214.5% upside from its current price of $2.23.

Amount of Analyst Coverage

Immix Biopharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Immix Biopharma are expected to grow in the coming year, from ($0.87) to ($0.85) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Immix Biopharma is -2.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Immix Biopharma is -2.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Immix Biopharma has a P/B Ratio of 4.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.71% of the float of Immix Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Immix Biopharma has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Immix Biopharma has recently decreased by 37.19%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Immix Biopharma does not currently pay a dividend.

Dividend Growth

Immix Biopharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.71% of the float of Immix Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Immix Biopharma has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Immix Biopharma has recently decreased by 37.19%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.78

News Sentiment

Immix Biopharma has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Immix Biopharma this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for IMMX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Immix Biopharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $10,061.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

55.40% of the stock of Immix Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 11.26% of the stock of Immix Biopharma is held by institutions.

IMMX Stock Analysis - Frequently Asked Questions

How have IMMX shares performed this year?

Immix Biopharma's stock was trading at $2.20 at the beginning of the year. Since then, IMMX shares have increased by 1.2% and is now trading at $2.2260.

How were Immix Biopharma's earnings last quarter?

Immix Biopharma, Inc. (NASDAQ:IMMX) released its quarterly earnings results on Friday, August, 8th. The company reported ($0.22) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by $0.01.

When did Immix Biopharma IPO?

Immix Biopharma (IMMX) raised $23 million in an IPO on Thursday, December 16th 2021. The company issued 4,200,000 shares at a price of $5.00-$6.00 per share.

Who are Immix Biopharma's major shareholders?

Top institutional shareholders of Immix Biopharma include Velan Capital Investment Management LP (0.09%) and Tritonpoint Wealth LLC (0.09%). Insiders that own company stock include Ilya M Rachman, Jason Hsu, Gabriel S Morris, Carey Ng, Helen C Adams and Magda Marquet.
View institutional ownership trends.

How do I buy shares of Immix Biopharma?

Shares of IMMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Immix Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Immix Biopharma investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Jabil (JBL), Disc Medicine (IRON), e.l.f. Beauty (ELF) and Adobe (ADBE).

Company Calendar

• Last Earnings: 8/08/2025
• Today: 9/10/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IMMX
• CIK: 1873835
• Web: www.immixbio.com
• Phone: 310-651-8041
• Fax: N/A
• Employees: 9
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Immix Biopharma: $7.00
• High Price Target: $7.00
• Low Price Target: $7.00
• Potential Upside/Downside: +207.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.77)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$21.61 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -205.35%
• Return on Assets: -110.63%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.23
• Quick Ratio: 1.23

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.48 per share
• Price / Book: 4.75

Miscellaneous

• Outstanding Shares: 28,830,000
• Free Float: 12,860,000
• Market Cap: $65.73 million
• Optionable: Optionable
• Beta: 0.25